In Vitro Activities of Eravacycline and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas

Antimicrob Agents Chemother. 2020 Jul 22;64(8):e00698-20. doi: 10.1128/AAC.00698-20. Print 2020 Jul 22.

Abstract

We performed in vitro susceptibility testing for eravacycline in comparison to 4 other antimicrobials against 10 Mycoplasma genitalium, 40 Mycoplasma hominis, 44 Mycoplasma pneumoniae, 20 Ureaplasma parvum, and 20 Ureaplasma urealyticum isolates. All eravacycline MICs were ≤0.25 μg/ml, except that for one isolate of M. genitalium, for which the MIC was 2 μg/ml. Eravacycline was markedly more potent than tetracycline, azithromycin, moxifloxacin, and clindamycin against all isolates tested, which included 37 macrolide, tetracycline, and/or fluoroquinolone-resistant organisms.

Keywords: eravacycline; mycoplasma; pneumonia; ureaplasma; urogenital infection.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Infective Agents*
  • Humans
  • Microbial Sensitivity Tests
  • Mycoplasma Infections* / drug therapy
  • Mycoplasma hominis
  • Tetracyclines / pharmacology
  • Ureaplasma
  • Ureaplasma Infections* / drug therapy
  • Ureaplasma urealyticum

Substances

  • Anti-Bacterial Agents
  • Anti-Infective Agents
  • Tetracyclines
  • eravacycline